Zoledronic

Osteoporosis, Chemotherapy, Osteoporosis + 10 more

Treatment

20 Active Studies for Zoledronic

What is Zoledronic

Zoledronic acid

The Generic name of this drug

Treatment Summary

Zoledronic acid, also known as CGP 42'446, is a medication used to prevent and treat osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. It was first described in 1994 and approved by the FDA in 2001. Zoledronic acid is similar to other drugs such as ibandronic acid, minodronic acid, and risedronic acid.

Zometa

is the brand name

image of different drug pills on a surface

Zoledronic Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zometa

Zoledronic acid

2001

53

Effectiveness

How Zoledronic Affects Patients

Zoledronic acid is a drug that helps prevent bone loss. It is safe to use, with few side effects, and produces long-lasting effects. However, there are some risks associated with taking this drug that patients should be aware of, such as electrolyte deficiencies, kidney damage, jawbone loss, unusual thigh fractures, breathing difficulties, liver problems, low calcium levels, and risks for pregnant women.

How Zoledronic works in the body

Bisphosphonates are taken into the bone, where they bind to substances that help the body break down the bone. Osteoclasts, which are responsible for breaking down the bone, then absorb bisphosphonates. These molecules cause the osteoclasts to detach from bones, preventing further bone resorption. Additionally, nitrogen-containing bisphosphonates like zoledronate are thought to cause tumor cells to die off by blocking certain proteins from forming. This leads to cell death and apoptosis.

When to interrupt dosage

The amount of Zoledronic is based on the identified affliction, including Bone Mineral Density, Paget’s Disease and Osteoporosis caused by glucocorticoid. The quantity fluctuates as per the method of delivery, as indicated in the table beneath.

Condition

Dosage

Administration

Osteoporosis

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Osteoporosis

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Bone Metastases

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Malignant Neoplasms

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Paget’s Disease

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Osteoporosis

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Chemotherapy

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Multiple Myeloma

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Osteoporosis

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Glucocorticoids

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Disease

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Postmenopause

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Osteitis Deformans

, 0.05 mg/mL, 4.0 mg/mL, 4.0 mg, 5.0 mg, 0.04 mg/mL, 0.8 mg/mL

, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Kit, Injection, Injection - Intravenous, Solution - Intravenous, Solution, Powder, for solution, Powder, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Zoledronic has four contraindications and must not be employed when encountering any of the disorders listed in the following table.

Zoledronic Contraindications

Condition

Risk Level

Notes

Renal Insufficiency, Chronic

Do Not Combine

Hypocalcemia

Do Not Combine

Acute Kidney Injury

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Zoledronic Acid may interact with Pulse Frequency

There are 10 known major drug interactions with Zoledronic.

Common Zoledronic Drug Interactions

Drug Name

Risk Level

Description

Alendronic acid

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.

Clodronic acid

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Clodronic acid.

Etidronic acid

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Etidronic acid.

Ibandronate

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Ibandronate.

Incadronic acid

Minor

The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Incadronic acid.

Zoledronic Toxicity & Overdose Risk

Overdosing on this drug may lead to problems with the kidneys, calcium, phosphorus, and magnesium levels in the body. Treatment for overdose involves giving the patient the missing ions through an intravenous injection.

image of a doctor in a lab doing drug, clinical research

Zoledronic Novel Uses: Which Conditions Have a Clinical Trial Featuring Zoledronic?

320 active studies are currently being conducted to explore the potential of Zoledronic acid in mitigating Osteoporosis, Malignant Neoplasms and Solid Tumors.

Condition

Clinical Trials

Trial Phases

Osteoporosis

3 Actively Recruiting

Not Applicable, Phase 2

Multiple Myeloma

6 Actively Recruiting

Phase 1, Phase 2

Bone Metastases

7 Actively Recruiting

Phase 4, Not Applicable, Phase 2, Phase 3

Disease

1 Actively Recruiting

Not Applicable

Osteoporosis

0 Actively Recruiting

Malignant Neoplasms

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Postmenopause

5 Actively Recruiting

Phase 2, Not Applicable

Glucocorticoids

0 Actively Recruiting

Paget’s Disease

0 Actively Recruiting

Osteoporosis

27 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2

Osteoporosis

0 Actively Recruiting

Osteitis Deformans

0 Actively Recruiting

Zoledronic Reviews: What are patients saying about Zoledronic?

5

Patient Review

11/30/2021

Zoledronic for Osteoporosis

I'm going in for my third infusion soon and have been really happy with the results. My bone density has improved, which is great considering my mom's osteoporosis. I haven't had any negative side effects so far, so I would definitely recommend this treatment to others.

5

Patient Review

11/30/2021

Zoledronic for Osteoporosis

I'm going in for my third infusion of this treatment soon, and it has been working great for me. I've had no side effects and it has improved my bone density significantly. My mother's hip broke due to her osteoporosis, so I'm grateful that this is helping me avoid the same fate.

3.3

Patient Review

9/12/2016

Zoledronic for Cancer that has Spread To the Bone From Solid Tumors

Ever since I started this monthly treatment, I've been having eye pain. It's only above my left eye, and it lasts for about a week each time. I have to take aspirins and Benadryl to make it go away. From what I can tell, this is a rare side effect of the medication, but it's still really frustrating.

3.3

Patient Review

9/12/2016

Zoledronic for Cancer that has Spread To the Bone From Solid Tumors

I've been on this monthly treatment since August 2016. Each time, I end up with a throbbing pain above my left eye that lasts for six days, no matter how many aspirins or Benadryls I take. From what I can tell, this is a rare side effect of the medication; however, the treatment is supposed to last for three years. Here's hoping it clears up soon.

2.7

Patient Review

3/10/2022

Zoledronic for Osteoporosis

I'm early on in the treatment process, but I had a severe reaction that caused flu-like symptoms and intense body aches that have lasted for over a week. I hope this isn't indicative of how the rest of the treatment will go, as the pain has been unbearable at times.

2.7

Patient Review

9/16/2022

Zoledronic for Osteoporosis

After being diagnosed with primary osteoporosis following a series of rib fractures, I received my first dose of zoledronic acid 18 hours ago. Unfortunately, it feels like all of my fractures have re-broken and I am in a great deal of pain.

2.7

Patient Review

3/10/2022

Zoledronic for Osteoporosis

I'm early on in the treatment, but I had a bad reaction that gave me flu-like symptoms: sickness and severe aches primarily in my upper body. It's been over a week and I'm still not feeling better. This was injected for bone marrow edema--I really hope the side effects don't continue because they're quite debilitating.

2.7

Patient Review

9/16/2022

Zoledronic for Osteoporosis

I was diagnosed with primary osteoporosis a few months ago after suffering from multiple rib fractures. I received my first dose of zoledronic acid 18 hours ago, and now feel like every fracture is broken again. This is terrible.

1.7

Patient Review

10/6/2022

Zoledronic for Cancer that has Spread To the Bone From Solid Tumors

I've only had this treatment three days ago, so I can't yet speak to its efficacy. However, the pain it has caused me is unlike anything I've ever experienced. It feels as if someone is inside my skeleton, scraping at it with a knife. I can hardly stand, let alone walk. The doctors say to take paracetamol—I must be experiencing some sort of rare reaction if that's their suggestion. Thankfully, I found this website and saw that others have had similar experiences.

1.7

Patient Review

10/6/2022

Zoledronic for Cancer that has Spread To the Bone From Solid Tumors

I can't speak to the efficacy of this treatment yet, but I can say that the pain is unbearable. It feels like someone is stabbing me in my bones. I haven't been able to walk since beginning this treatment and doctors just tell me to take acetaminophen-- as if that's going to help! Thankful to find others with similar experiences online.

1

Patient Review

3/23/2019

Zoledronic for Osteoporosis

This is the worst drug I've ever taken. Four months later and I'm still in pain. This caused ringing in my ears and problems with my bones. My arthritis flared up immediately after taking this, and I'm still suffering from it. I wish I'd never taken it.

1

Patient Review

12/7/2018

Zoledronic for Osteoporosis

Do not take this drug. I was hospitalized just five days after receiving the infusion, due to a high fever and body aches. It's now December and I'm still feeling the effects of this terrible medication.

1

Patient Review

11/12/2022

Zoledronic for Osteoporosis

I received this treatment and, that night, I was in a great deal of pain. I also developed a kidney infection which required antibiotics to clear up. Even after two weeks, I'm still not feeling well. I urge you to avoid this treatment if possible.

1

Patient Review

3/23/2019

Zoledronic for Osteoporosis

This is by far the worst drug I've ever taken. I'm four months in and still experiencing a range of awful side effects, including but not limited to tinnitus and problems with my bones in my ears. The company tried telling me it was caused by smoking, which is absolute rubbish – it happened immediately after the infusion. They don't seem to care about the long-term risks of this treatment; all they care about is making money. This has destroyed me.

1

Patient Review

11/12/2022

Zoledronic for Osteoporosis

I ended up with a kidney infection after this treatment that left me feeling exhausted and in pain for weeks. I wouldn't recommend it to anyone.

1

Patient Review

12/7/2018

Zoledronic for Osteoporosis

Do not take this drug! I was hospitalized just five days after receiving the infusion. I had a fever of 104, couldn't walk or breathe, and my entire body ached. It's now December 7th and I'm STILL experiencing side effects.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zoledronic

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the side effect of zoledronic acid?

"The most common adverse effect associated with zoledronic acid infusion is fever. Sometimes people also report feeling like they have the flu, including fever, chills, bone pain, and/or joint pain and muscle pain. These symptoms usually go away within 24 to 48 hours and don't usually require treatment."

Answered by AI

Is zoledronic acid a form of chemotherapy?

"Zoledronic acid is not a cancer chemotherapy, and will not slow or stop the spread of cancer, but can be used to treat bone disease in cancer patients. It is a medication in the class of bisphosphonates."

Answered by AI

What is the drug zoledronic used for?

"Zoledronic acid injection is used to treat hypercalcemia by helping to reduce the levels of calcium in the blood in patients with some types of cancer."

Answered by AI

What is a zoledronic infusion?

"Aclasta is an osteoporosis medication prescribed to help strengthen your bones and reduce your risk of breaking a bone. Zoledronic acid, the active ingredient in Aclasta, is a 'bisphosphonate' - a group of medications that work by slowing down the cells that break down bone. Aclasta is available as an annual intravenous infusion (drip)."

Answered by AI

Clinical Trials for Zoledronic

Image of UC San Diego in San Diego, United States.

Epione Device for Bone Conditions

18+
All Sexes
San Diego, CA

The goal of this investigational device exemption is to evaluate the Epione assistance for introducer placement during percutaneous procedures in musculo-skeletic (MSK) structures of the pelvis and the spine in adults. The main question is the determination of the rate of feasible procedures assisted by the Epione device Participants will undergo their procedure(s) as planned by their physician. If they accept to participate to the study, the differences with standard of care will be: * The use of the Epione device to place the introducer(s), instead of freehand placement if they do not participate * Additional CT or CBCT scans during the procedure.

Waitlist Available
Has No Placebo

UC San Diego (+2 Sites)

Sean Tutton, MD

Quantum Surgical

Image of University of Waterloo in Waterloo, Canada.

Virtual Chiropractic Intervention for Spinal Fracture

18+
All Sexes
Waterloo, Canada

This study will determine feasibility of a chiropractor delivered virtual intervention for individuals following osteoporotic vertebral fracture. This pilot trial will have two parallel groups with a 1:1 ratio. Participants will be randomized to: 1) immediate receipt; or 2) waitlist usual care control and delayed receipt of VIVA 10 weeks post-randomization. VIVA is an intervention for people with vertebral fractures that covers four areas: pain management, safe movement, exercise, and nutrition. It includes print and video resources, and a framework for goal setting, selecting exercises, and teaching body mechanics. A chiropractor (DC) completes a virtual assessment and then leads twelve 1:1 virtual sessions (via Zoom) over eight weeks. Sessions start with brief education on a topic (e.g., safe movement, pain management, exercise, nutrition), followed by training and modeling of exercise and safe movement strategies, then goal setting, and action planning. This trial will be considered feasible if a) we recruit 14 people in eight months; b) 80% of participants complete the trial; and c) exercise adherence is 75%.

Recruiting
Has No Placebo

University of Waterloo

Image of UPMC Hillman Cancer Center in Pittsburgh, United States.

Mobile App for Cancer

18+
All Sexes
Pittsburgh, PA

The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings via study application. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).

Waitlist Available
Has No Placebo

UPMC Hillman Cancer Center

Carissa A Low

Have you considered Zoledronic clinical trials?

We made a collection of clinical trials featuring Zoledronic, we think they might fit your search criteria.
Go to Trials
Image of University of Virginia Medical Center in Charlottesville, United States.

Estrogen for Bone Health in Amenorrhea

14 - 25
Female
Charlottesville, VA

The purpose of this study is to assess whether the natural form of estrogen (17-beta estradiol) given as a patch so that it is absorbed through your skin, is better at improving bone strength over 1 year than natural estrogen (17-beta estradiol) taken by mouth, or a synthetic form oestrogen (ethinyl estradiol) given as a patch that also provides birth control. Participants will: Take estrogen for 1 year either (i) in its natural form as a patch twice a week (and progesterone by mouth for 12 days of each month), or (ii) in its natural form as a pill daily (and progesterone by mouth for 12 days of each month), or (iii) in a synthetic form as a birth control patch weekly for 3 weeks with 1 week off the patch. You will not be able to choose which form of estrogen you will receive as this will be assigned to you based on a pre-existing randomization sequence (like the flip of a coin) Take provided calcium and vitamin D supplements Attend 4 study visits over 12 months with two at the beginning and then every 6 months that include: History and Physical Exams Lab Work Imaging studies Questionnaires Dietary recalls

Phase 2
Recruiting

University of Virginia Medical Center (+1 Sites)

Madhusmita Misra, MD, MPH

Image of Rutgers University - NJ Inst Food Nutrition & Health in New Brunswick, United States.

Peanut Snacks for Weight Loss

50 - 75
All Sexes
New Brunswick, NJ

The aging population is rapidly increasing, and it is important to identify dietary factors that can prevent disease and promote health in this group. Legumes, such as peanuts, are a plant-based food high in protein and unsaturated fat making this a healthy choice but are not consumed frequently enough in older adults. Studies have shown that regular nut consumption is associated with lower adiposity and reduced weight gain, and several dietary pattern studies indicate that nuts and legumes are associated with better bone health. In addition, our preliminary translational data indicates that a higher monounsaturated fatty acid (MUFA) intake is associated with improved bone mineral density (BMD) and quality. Given these findings, the proposed study aims to examine the impact of consuming peanut products on bone health, metabolic health (e.g., serum glucose, insulin, lipids and inflammation), markers of brain and sleep health, and physical function in overweight and obese older adults before and after a six-month weight loss intervention using a randomized controlled design. The results of this study have the potential to provide valuable insights into the role of peanuts as a sources of fatty acids in promoting health and preventing disease in at-risk adults.

Recruiting
Has No Placebo

Rutgers University - NJ Inst Food Nutrition & Health

Have you considered Zoledronic clinical trials?

We made a collection of clinical trials featuring Zoledronic, we think they might fit your search criteria.
Go to Trials
Image of Don tyson Center for Agricultural Sciencers in Fayetteville, United States.

Protein and Exercise for Postmenopausal Women

Any Age
Female
Fayetteville, AR

The goal of this clinical trial is to learn if consuming a higher protein diet that includes one serving of beef each day, in combination with resistance exercise, improves wellbeing in postmenopausal women. It will also tell us about how higher protein intake changes body composition and blood values related to health. The main questions it aims to answer are: * Does higher protein intake combined with resistance training improve mood and sleep in postmenopausal women? * What other health benefits to postmenopausal women experience when the follow a higher protein diet and participate in resistance exercise? Researchers will compare three groups 1) postmenopausal women living their daily lives as usual, 2) postmenopausal women consuming a higher protein diet, and 2) postmenopausal women consuming a higher protein diet and participating in resistance training. Participants will: * Consume a higher protein diet for 16 weeks * Participate in an at-home resistance training for 16 weeks * Keep a diary of their food intake, sleep habits, and mood * Have health assessments every 4 weeks

Recruiting
Has No Placebo

Don tyson Center for Agricultural Sciencers (+1 Sites)

Jamie Baum

Image of The Buck Institute for Research on Aging in Novato, United States.

GLYLO Supplement for Postmenopausal Aging

45 - 65
Female
Novato, CA

The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline. This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.

Recruiting
Advanced

The Buck Institute for Research on Aging

Image of University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology in Baltimore, United States.

OPTIONS Program for Osteoporosis

65+
All Sexes
Baltimore, MD

Osteoporosis is a disease that weakens bones so the bones may break easily. The risk for osteoporosis increases with age in both women and men. Osteoporosis affects 10 million older adults in the US. Osteoporosis is a common cause of broken bones in the hips and legs. Broken bones can lead to disability, nursing home placement, and death. Because of the dire consequences, a broken hip or leg is one of the most dreaded injuries for older adults. Many studies confirm that a simple regimen of exercise, healthy diet and bone-strengthening medications can improve overall recovery after a broken hip or leg. This regimen can prevent a person from becoming disabled, having future fractures, and even prevent death. Many older adults have surgery in a hospital after breaking a hip or leg. Then older adults go to a skilled nursing facility (SNF) for rehabilitation. Care in SNFs varies greatly. Some patients do not receive the regimen that the investigators know is most beneficial to improve bone health and recovery. Even patients who get exercise, healthy diet, and bone-strengthening medication in the SNF, may not continue with the regimen once patients go home. Therefore, the investigators want to implement and test OsteoPorotic fracTure preventION System (OPTIONS). OPTIONS is a program that will integrate the regimen into the care that is provided in SNFs and after discharge to the community. OPTONS will provide information about exercise, diet, and bone-strengthening medication. OPTIONS will provide doctors, clinical staff, patients, and care partners with the information these stakeholders need to carry out the best-practice regimen. The investigators are partnering with PointClickCare, a large cloud-based healthcare software provider, with SNFs and community care sites across the US. The investigators will include 32 SNFs from different US areas. The investigators will flip a coin to assign SNFs to the intervention (OPTIONS) or the control arm (enhanced usual care) of the study. Enhanced usual care is the care that is typically provided in SNFs after a fracture and adding information about a publicly available fall prevention toolkit. The investigators are using an "implementation science" approach that requires the investigators to get input from the OPTIONS study's vast stakeholder community throughout the study. The OPTIONS study's stakeholders include patients, care partners, clinicians, and professional organizations. The research question is, can using OPTIONS in SNFs and in the community after discharge improve physical function and quality of life in older people in the year after a hip or leg fracture? The investigators are measuring patient-reported outcomes. The investigators will include 1553 patients across the 32 facilities. The investigators have selected outcomes that are important to patients. Specifically, the investigators are measuring patient-reported function and quality of life. The investigators are also measuring patient-reported falls and fractures. The investigators will track the number of patients who die during the study. This study's hypothesis is that patients who receive OPTIONS will report better physical function (i.e., can walk and take better care of themselves) than those who receive enhanced usual care. The investigators also hypothesize that patients that receive OPTIONS will report a better quality of life than those who receive enhanced usual care. This study will provide sound data about the effectiveness of OPTIONS. OPTIONS could then be spread to other SNFs and community-based programs. This would ensure that all older people receive the right care after a hip or leg fracture.

Waitlist Available
Has No Placebo

University of Maryland, Baltimore, Department of Epidemiology and Public Health, Division of Gerontology (+1 Sites)

Denise Orwig, PhD

Image of Arthritis Research Canada in Vancouver, Canada.

Virtual Rehabilitation for Spinal Fracture

18+
All Sexes
Vancouver, Canada

Spine fractures are the most common fracture due to osteoporosis. They happen during falls or activities of daily life, like bending to tie shoes. Fractures of the spine can result in pain, which can sometimes last for a long time. Spine fractures can affect breathing, appetite, digestion, and mobility, and can restrict or modify people's work or daily activities. There are no standard rehabilitation programs after spine fracture, and patients often have to pay for rehabilitation. Rehabilitation can be hard to access, especially in rural or remote locations. It can be hard to find health care or rehabilitation providers who specialize in treating spine fractures. After reviewing research and consulting patients and health care providers to understand their experiences with spine fracture rehabilitation, the research team developed a toolkit for a virtual rehabilitation program for people with spine fractures, called VIVA. The research team wants to submit a grant for a clinical trial to implement VIVA in five provinces and determine if VIVA reduces pain and improves physical functioning and quality of life, and if the benefits outweigh the costs. Before this, the team proposes to do a pilot study to test how feasible it is to do a study of VIVA in three provinces.

Waitlist Available
Has No Placebo

Arthritis Research Canada (+5 Sites)

Lora Giangregorio, PhD

Have you considered Zoledronic clinical trials?

We made a collection of clinical trials featuring Zoledronic, we think they might fit your search criteria.
Go to Trials